RT Journal Article
SR Electronic
T1 Liver transplantation without graft ischemia in humans
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.20.20065979
DO 10.1101/2020.04.20.20065979
A1 Guo, Zhiyong
A1 Zhao, Qiang
A1 Huang, Shanzhou
A1 Huang, Changjun
A1 Zhang, Jian
A1 Wang, Dongping
A1 Yang, Lu
A1 Chen, Maogen
A1 Wu, Linwei
A1 Zhang, Zhiheng
A1 Zhu, Zebin
A1 Wang, Linhe
A1 Zhu, Caihui
A1 Zhang, Yixi
A1 Tang, Yunhua
A1 Sun, Chengjun
A1 Xiong, Wei
A1 Shen, Yuekun
A1 Chen, Xiaoxiang
A1 Xu, Jinghong
A1 Wang, Tielong
A1 Ma, Yi
A1 Hu, Anbin
A1 Chen, Yinghua
A1 Zhu, Xiaofeng
A1 Rong, Jian
A1 Cai, Changjie
A1 Gong, Fengqiu
A1 Guan, Xiangdong
A1 Huang, Wenqi
A1 Ko, Dicken Shiu-Chung
A1 Li, Xianchang
A1 Huang, Jiefu
A1 Ju, Weiqiang
A1 He, Xiaoshun
YR 2020
UL http://medrxiv.org/content/early/2020/04/24/2020.04.20.20065979.abstract
AB BACKGROUND Ischemia-reperfusion injury is considered an inevitable event that compromises posttransplant outcomes. Numerous treatments have been proposed to reduce its impact. However, most of them have had limited success, as none of them can completely avoid graft ischemia.METHODS Ischemia-free liver transplantation (IFLT) comprises surgical techniques to enable continuous oxygenated blood supply to brain-dead donor livers during procurement, preservation and implantation using normothermic machine perfusion technology. In this nonrandomized study, 38 donor livers were transplanted using IFLT and were compared to 130 livers procured and transplanted using a conventional procedure (CLT).RESULTS One patient (2.6%) suffered early allograft dysfunction in the IFLT group, compared with 43.8% of patients in the CLT group (absolute risk difference, 41.2 percentage points; 95% confidence interval, −31.3, −51.1). The median (range) peak aspartate aminotransferase levels within the first week (336, 149-4112 vs. 1445, 149-25083 U/L, P<0.001), and the median (range) total bilirubin levels on day 7 (2.11, 0.68-12.47 vs. 5.11, 0.56-51.97 mg/dL, P<0.001) posttransplantation were much lower in the IFLT than in the CLT group. The IFLT recipients had less need for renal replacement therapy (2.6% vs. 16.9%, P=0.02), shorter median (range) intensive care unit stay (34, 12-235 vs. 43.5, 7-936 hours, P=0.003), and higher one-year recipient survival (97.4% vs. 84.6%, P=0.02) and graft survival (94.7% vs. 83.8%, P=0.04) rates than the CLT recipients. The extended criteria donor livers in IFLT yielded faster posttransplant recovery than the standard criteria donor livers in CLT.CONCLUSIONS IFLT provides a new approach to minimize ischemia-reperfusion injury and improve post-transplant outcomes.Clinical trial registry This trial is registered with http://www.chictr.org.cn, number ChiCTR-OPN-17012090.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialChiCTR-OPN-17012090Funding StatementThis work is supported by grants as follows: the National Natural Science Foundation of China (81970564, 81471583 and 81570587), the Key Clinical Specialty Construction Project of National Health and Family Planning Commission of the People's Republic of China, the Guangdong Provincial Key Laboratory Construction Projection on Organ Donation and Transplant Immunology (2013A061401007, 2017B030314018), Guangdong Provincial international Cooperation Base of Science and Technology (Organ Transplantation) (2015B050501002), Guangdong Provincial Natural Science Funds for Major Basic Science Culture Project (2015A030308010), Guangdong Provincial Natural Science Funds for Distinguished Young Scholars (2015A030306025), Special support program for training high level talents in Guangdong Province (2015TQ01R168), Pearl River Nova Program of Guangzhou (201506010014), Science and Technology Program of Guangzhou (201704020150), Sun Yat-sen University Young Teacher Key Cultivate Project (17ykzd29) and "Elite program" specially supported by China organ transplantation development foundation.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data needed to evaluate the conclusions in the paper are present in the paper or the supplementary materials.